Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer

Bayoglu, Ibrahim; Yildiz, Ibrahim; Varol, Umut; Cokmert, Suna; Kucukzeybek, Yuksel; Alacacioglu, Ahmet; Demir, LÜTFİYE; Dirican, Ahmet; Akyol, Murat; Yildiz, Yasar; Tarhan, Mustafa

Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer

Bayoglu I. V., Yildiz I., Varol U., Cokmert S., Kucukzeybek Y., Alacacioglu A., ...Daha Fazla

JOURNAL OF BUON, cilt.20, ss.460-467, 2015 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 20
Basım Tarihi: 2015
Dergi Adı: JOURNAL OF BUON
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.460-467
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Eskişehir Osmangazi Üniversitesi Adresli: Hayır

Özet

Purpose: Currently, there are several oxaliplatin combination regimens for first-line therapy of metastatic colorectal cancer (mCRC). In this study, we compared the survival outcomes of mCRC patients treated with bevacizumab in combination with either modified 5-FU/FA/oxaliplatin (rnFOLFOX6) or capecitabine/oxaliplatin (XELOX).